Top

Published in:

01-01-2009 | Report

The surgical margin status after breast-conserving surgery: discussion of an open issue

Authors: Alberto Luini, Joel Rososchansky, Giovanna Gatti, Stefano Zurrida, Pietro Caldarella, Giuseppe Viale, Gabriela Rosali dos Santos, Antonio Frasson

Published in: Breast Cancer Research and Treatment | Issue 2/2009

Abstract

Hypothesis The best therapeutic approach to the involved or proximal surgical margins has not been defined yet; surgical margins status can influence the local relapse of disease in breast carcinoma, but the impact on overall survival has not been clearly demonstrated. Purpose of this work is to find in the available literature further evidence to guide the therapeutic behaviour in patients with close margins by invasive carcinoma. Design Review of the currently available literature on the evaluation of surgical margins in breast conserving surgery; influence of margin involvement by invasive component or intraductal component. Patients or other participants Literature research by PubMed on the topics of breast carcinoma, conservative surgery and margin definition and status; therapeutic approach to involved margins. Main outcome measure We reviewed the available literature focusing our attention to the definition of clear surgical margins and to the value of the close proximity of margins in relation to the local control of disease and the best therapeutic management of different situations. Results Further evidence is needed on large numbers of patients to understand how to evaluate surgical margins in invasive breast carcinoma. Conclusions There is no consensus on the definition of “clear surgical margins”, and the ideal approach to the close proximity of margins has not been defined. It is not sure whether a new surgical procedure is really needed in every case of close proximity of tumor cells to the margins. Radiation therapy could be a good option in the management of these cases, but further evidence is needed to establish the real impact of clear surgical margins on local control of disease and, furthermore, on survival.

Fisher B, Dignam J, Wolmark N et al (1998) Lumpectomy and radiation therapy for the treatment of intraductal breast cancer. Findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 16:441–452PubMed

Fisher ER, Dignam J, Tan-Chiu E et al (1999) Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP): eight-year update of protocol B-17. Cancer 86:429–438PubMedCrossRef

Fisher ER, Costantino J, Fisher B et al (1995) Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) protocol B-17. Cancer 75:1310–1319PubMedCrossRef

Ikeda T, Akiyama F, Hiraoka M et al (1999) Surgical margin status as a cause of local failure after breast conserving therapy. Breast Cancer 6:93–97PubMedCrossRef

Gage I, Schnitt SJ, Nixon AJ et al (1996) Pathologic margin involvement and the risk of recurrence in patients treated with breast-conserving therapy. Cancer 9:1921–1928CrossRef

Anscher MS, Jones P, Prosnitz LR et al (1993) Local failure and margin status in early stage breast carcinoma treated with conservation surgery and radiation therapy. Ann Surg 218:22–28PubMedCrossRef

Tafra L, Guenter J, Giuliano A (1993) Planeed segmentectomy: a necessity for breast carcinoma. Arch Surg 128:1014–1020PubMed

Park CC, Mitsumori M, Nixon A et al (2000) Outcome at 8 years after breast-conserving surgery and radiation therapy for invasive breast cancer: influence of margin status and systemic therapy on local recurrence. J Clin Oncol 8:1668–1675

Freedman G, Fowble B, Hanlon A et al (1999) Patients with early stage invasive cancer with close or positive margins treated with conservative surgery and radiation have an increased risk of breast recurrence that is delayed by adjuvant systemic therapy. Int J Radiat Oncol Biol Phys 44:1005–1015PubMed

10.

Wazer DE, DiPetrillo T, Schmidt-Ulrich RK, Weld L et al (1992) Factors influencing cosmetic outcome and complication risk after conservative surgery and radiotherapy for early stage breast carcinoma. J Clin Oncol 10:356–363PubMed

11.

Smitt MC, Nowels KW, Zdeblick MJ et al (1995) The importance of the lumpectomy surgical margin status in long-term results of breast conservation. Cancer 76:259–267PubMedCrossRef

12.

Papa MZ, Zippel D, Koller M et al (1999) Positive margins of breast biopsy : is reexcision always necessary? J Surg Oncol 70:167–171PubMedCrossRef

13.

Peterson ME, Schultz DJ, Reynolds C et al (1999) Outcome in breast cancer patients relative to margin status after treatment with breast-conserving surgery and radiation therapy. The University of Pennsylvania experience. Int J Radiat Oncol Biol Phys 43:1029–1035PubMedCrossRef

14.

Schnitt SJ, Abner A, Gelman R et al (1994) The relationship between microscopic margins of resection and the risk of local recurrence in patients with breast cancer treated with breast-conserving surgery and radiation therapy. Cancer 74:1746–1751PubMedCrossRef

15.

Pittinger TP, Maronian NC, Poulter CA et al (1994) Importance of margin status in outcome of breast-conserving surgery for carcinoma. Surgery 116:605–609PubMed

16.

Vicini FA, Kestin LL, Goldstein NS et al (2001) Relationship between excision volume, margin status, and tumor size with the development of local recurrence in patients with ductal carcinoma in situ treated with breast-conserving therapy. J Surg Oncol 76:245–254PubMedCrossRef

17.

Wazer DE, Schmidt- Ullrich RK, Schmid CH et al (1997) The value of breast lumpectomy margin assessment as a predictor of residual tumor burden. Int J Radiat Oncol Biol Phys 38:291–299PubMed

18.

Park CC, Mitsumori M, Reacht A et al (1998) The relationship between pathologic margin status and outcome after breast-conserving therapy (Abstr). Int J Radiat Oncol Biol Phys 42:125

19.

Solin LJ, Fowble BL, Schultz DJ et al (1991) The significance of the pathology margins of the tumor excision on the outcome of patients treated with definitive irradiation for early stage breast cancer. Int J Radiat Oncol Biol Phys 21:279–287PubMed

20.

Neuschatz AC, DiPetrillo T, Steinhoff M et al (2002) The value of breast lumpectomy margin assessment as a predictor of residual tumor burden in ductal carcinoma in situ of the breast. Cancer 94:1917–1924PubMedCrossRef

21.

Swanson GP, Rynearson K, Symmonds R (2002) Significance of margins of excision on breast cancer recurrence. Am J Clin Oncol (CCT) 5:438–441CrossRef

22.

Sauter ER, Hoffman JP, Ottery FD et al (1994) Is frozen section analysis of reexcision lumpectomy margins worthwhile? Margin analysis in breast reexcisions. Cancer 73:2607–2612PubMedCrossRef

23.

Wazer DE, Schmidt-Ulrich RK, Ruthazer R et al (1998) Factors determining outcome for breast-conserving irradiation with margin-directed dose escalation to the tumor bed. Int J Radiat Oncol Biol Phys 40:851–858PubMedCrossRef

24.

Spivack B, Khanna MM, Tafra L et al (1994) Margins status and local recurrence after breast conserving surgery. Arch Surg 129:952–956PubMed

25.

Sneige N, Mc Neese, Atkinson EN et al (1995) Ductal carcinoma in situ treated with lumpectomy and irradiation: histopathological analysis of 49 specimens with emphasis on risk factors and long term results. Hum Pathol 26:642–649PubMedCrossRef

26.

DiBiase SJ, Komarnicky LT, Heron DE et al (2002) Influence of radiation dose on positive surgical margins in women undergoing breast conservation therapy. Int J Radiat Oncol Biol Phys 3:680–686

27.

Tartter PI, Kaplan J, Bleiweiss I et al (2000) Lumpectomy margins, reexcision, and local recurrence of breast cancer. Am J Surg 179:81–85PubMedCrossRef

28.

Silverstein MJ, Waisman JR, Gamagami P et al (1990) Intraductal carcinoma of the breast (208 cases): clinical factors influencing treatment choice. Cancer 66:102–108PubMedCrossRef

29.

Solin LJ, Kurtz J, Fourquet A et al (1996) Fifteen-year results of breast-conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast. J Clin Oncol 14:754–763PubMed

30.

Silverstein MJ, Cohlan BF, Gierson ED et al (1992) Duct carcinoma in situ: 227 cases without microinvasion. Eur J Cancer 28:630–634PubMedCrossRef

31.

Schwartz GF, Solin LJ, Olivotto IA et al (2000) Consensus conference on the treatment of in situ ductal carcinoma of the breast, April 22–25, 1999. Cancer 88:946–954PubMedCrossRef

32.

Van Zee KJ, Liberman L, Samli B et al (1999) Long term follow-up of women with ductal carcinoma in situ treated with breast-conserving surgery: the effect of age. Cancer 86:1757–1767PubMedCrossRef

33.

Solin LJ, Yeh I, Kurtz J et al (1993) Ductal carcinoma in situ (intraductal carcinoma) of the breast treated with breast-conserving surgery and definitive irradiation. Cancer 71:2532–2542PubMedCrossRef

34.

Veronesi U, Marubini E, Mariani L, Galimberti V, Luini A, Veronesi P, Salvadori B, Zucali R (2001) Radiotherapy after breast-conserving surgery in small breast carcinoma: long-term results of a randomized trial. Ann Oncol 12(7):997–1003PubMedCrossRef

35.

Ryoo MC, Kagan AR, Wollin M et al (1989) Prognostic factors for recurrence and cosmesis in 393 patients after radiation therapy for early mammary carcinoma. Radiology 172:555–559PubMed

36.

Heimann R, Powers C, Halpern HJ et al (1996) Breast preservation in stage I and II carcinoma of the breast. The university of Chicago experience. Cancer 78:1722–1730PubMedCrossRef

37.

Julien JP, Bijker N, Fentiman IS et al (2000) Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomized phase III trial 10853. Lancet 355:528–533PubMedCrossRef

38.

Kurtz JM (1992) Factors influencing the risk of local recurrence in the breast. Eur J Cancer 28:660–666PubMedCrossRef

39.

Borger J, Kemperman H, Hart A et al (1994) Risk factors in breast conservation therapy. J Clin Oncol 12:653–660PubMed

40.

Darvishian F, Hajdu SI, DeRisi DC (2003) Significance of linear extent of breast carcinoma at surgical margin. Ann Surg Oncol 1:48–51CrossRef

41.

Mirza NQ, Vlastos G, Meric F et al (2002) Predictors of locoregional recurrence among patients with early-stage breast cancer treated with breast-conserving therapy. Ann Surg Oncol 9:256–265PubMedCrossRef

42.

Ohsumi S, Takashima S, Saeki T, Aogi K (2002) Breast-conserving therapy of wide excision, axillary dissection, and radiotherapy for early-stage breast cancer: the experience of the National Shikoku Cancer Center. Biomed Pharmacother 56:196–200CrossRef

43.

Silverstein MJ, Lagios MD, Groshem S et al (1999) The influence of margin width on local control of ductal carcinoma in situ of the breast. N Engl J Med 340:1455–1461PubMedCrossRef

44.

Clarke DH, Le MG, Sarrazing D et al (1985) Analysis of local regional relapses in patients with early breast cancers treated by excision and radiotherapy: experience of the institute Gustave-Roussy. Int J Radiat Oncol Biol Phys 11:137–145PubMed

45.

Dewar JA, Arriagada R, Benhamou S et al (1995) Local relapse and contralateral tumor rates in patients with breast cancer treated with conservative surgery and radiotherapy (Institut Gustave Roussy 1970–1982). Cancer 76:2260–2265PubMedCrossRef

46.

Forquet A, Campana F, Zafrani B et al (1989) Prognostic factors of breast recurrence in the conservative management of early breast cancer: a 25-years follow-up. Int J Radiat Oncol Biol Phys 17:719–725

47.

Veronesi U, Salvadori B, Luini A, Greco M, Saccozzi R, del Vecchio M, Mariani L, Zurrida S, Rilke F (1995) Breast conservation is a safe method in patients with small cancer of the breast. Long-term results of three randomised trials on 1,973 patients. Eur J Cancer 31A(10):1574–1579PubMedCrossRef

48.

Zurrida S, Costa A, Luini A et al (2001) The Veronesi quadrantectomy: an established procedure for the conservative treatment of early breast cancer. Int J Surg Investig 2(6):423–431PubMed

49.

Holland PA, Gandhi A, Knox WF, Wilson M, Baildam AD, Bundred NJ (1998) The importance of complete excision in the prevention of local recurrence of ductal carcinoma in situ. Br J Cancer 77:110–114PubMed

50.

Veronesi U, Volterrani F, Luini A et al (1990) Quadrantectomy versus lumpectomy for small size breast cancer. Eur J Cancer 26(6):671–673PubMedCrossRef

51.

Wallgren A, Bonetti M, Gelber RD et al (2003) Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. J Clin Oncol 21:1205–1213PubMedCrossRef

Title: The surgical margin status after breast-conserving surgery: discussion of an open issue
Authors: Alberto Luini
Joel Rososchansky
Giovanna Gatti
Stefano Zurrida
Pietro Caldarella
Giuseppe Viale
Gabriela Rosali dos Santos
Antonio Frasson
Publication date: 01-01-2009
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2009
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-008-9929-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2009

Gene expression meta-analysis identifies chromosomal regions and candidate genes involved in breast cancer metastasis

Elevated chemokine receptor CXCR4 expression in primary tumors following neoadjuvant chemotherapy predicts poor outcomes for patients with locally advanced breast cancer (LABC)

Deleterious CHEK2 1100delC and L303X mutants identified among 38 human breast cancer cell lines

BRCA1 E1644X: a deleterious mutation in an African American individual with early onset breast cancer

Evaluation of the BRCA1 interacting genes RAP80 and CCDC98 in familial breast cancer susceptibility

Germline RAP80 mutations and susceptibility to breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer